In particular, in a phase 2 clinical trial, patients with BRAF V600E-mutant lung cancer were found to benefit clinically from vemurafenib, a BRAF inhibitor authorized for the treatment of BRAF V600E-mutant melanoma [79]. This evidence concerns the gene BRAF and lung carcinoma.